Synthetic platelets
AssigneeCase Western Reserve University
InventorsAnirban Sen Gupta, Christa Pawloski
Life of this patent
Estimating the term…
Abstract
A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.
Claims37
A synthetic platelet comprising:
- a biocompatible flexible nanoparticle including an outer surface and a plurality of site targeted peptides conjugated to the surface;
- and
- a therapeutic agent, wherein the therapeutic agent is encapsulated by and/or conjugated to the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.
A method of treating a vascular injury in a subject, the method comprising:
- administering to a site of vascular injury in a subject a synthetic platelet comprising a biocompatible flexible nanoparticle and a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle,
- wherein the synthetic platelet includes an outer surface, a plurality of peptides conjugated to the surface, the peptides including a plurality of von Willebrand factor-binding peptides (VBPs), collagen-binding peptides (CBPs) and active platelet GPIIb-IIIa-binding peptides (GBPs),
- wherein the synthetic platelet adheres to a vascular surface, vascular disease site, and/or vascular injury site with exposed von Willebrand factor and collagen, wherein the synthetic platelet promotes arrest and aggregation of active platelets onto sites of the synthetic platelet adhesion, and
- wherein the synthetic platelet promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site of vascular injury via a site-relevant enzyme.
A method of treating a vascular occlusive condition in a subject,
- administering to a subject a synthetic platelet comprising a biocompatible flexible nanoparticle and a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle,
- wherein the synthetic platelet includes an outer surface, a plurality of peptides conjugated to the surface, the peptides including a plurality of active platelet GPIIb-IIIa-binding peptides (GBPs) and active platelet p-selectin binding peptides, and wherein the synthetic platelet adheres to an active platelet rich thrombus site and promotes delivery of the therapeutic agent onto sites of the active platelet rich thrombus.
A method of treating a traumatic brain injury (TBI) in a subject, the method comprising:
- administering to a subject a synthetic platelet comprising a biocompatible flexible nanoparticle and a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle,
- wherein the synthetic platelet includes an outer surface, a plurality of peptides conjugated to the surface, the peptides including a plurality of brain injury site-targeting peptides, wherein the synthetic platelet adheres to a brain injury site and promotes delivery of the therapeutic agent onto sites of the brain injury.
Dependencies are inferred from the claim text.